SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL

Splash Beverage Group (SBEV) announced an exclusive global licensing agreement with Argent BioPharma (RGT) for CannEpil®, a proprietary, patent-protected product. The release does not cite any financial terms, milestones, or near-term revenue impact, suggesting limited immediate market-moving information.

Analysis

Splash Beverage Group (SBEV) announced an exclusive global licensing agreement with Argent BioPharma (RGT) for CannEpil®, a proprietary, patent-protected product. The release does not cite any financial terms, milestones, or near-term revenue impact, suggesting limited immediate market-moving information.